Search | OpenScholar

Search results

1963 results found

Expanding phenomenologic heterogeneity of tardive syndromes: Time for an updated assessment tool. Parkinsonism Relat Disord 2020;77:141-145.

Publication: Journal Article

Bhidayasiri, R, JM Kane, KP Frei, SN Caroff, CU Correll, S Fahn, J Jankovic, RA Hauser, and DD Truong. 2020. “Expanding Phenomenologic Heterogeneity of Tardive Syndromes: Time for an Updated Assessment Tool. Parkinsonism Relat Disord 2020;77:141-145.”. Parkonsonism Relat Disord.

Standing and Supine Blood Pressure Outcomes Associated With Droxidopa and Midodrine in Patients With Neurogenic Orthostatic Hypotension: A Bayesian Meta-analysis and Mixed Treatment Comparison of Randomized Trials. 2018;52:1182-1194.

Publication: Journal Article

Chen, JJ, Y Han, J Tang, L Portillo, RA Hauser, and K Dashtipour. 2018. “Standing and Supine Blood Pressure Outcomes Associated With Droxidopa and Midodrine in Patients With Neurogenic Orthostatic Hypotension: A Bayesian Meta-Analysis and Mixed Treatment Comparison of Randomized Trials. 2018;52:1182-1194.”. Ann Pharmacother.

Use, maintenance and dose effects of cognitive speed of processing training in Parkinson's disease. Int J Neurosci 2017;127:841-848.

Publication: Journal Article

Valdes, EG, ML O’Connor, EY Uc, RA Hauser, R Andel, and JD Edwards. 2017. “Use, Maintenance and Dose Effects of Cognitive Speed of Processing Training in Parkinson’s Disease. Int J Neurosci 2017;127:841-848.”. Int J Neurosci.

Randomized Trial of Preladenant, Given as Monotherapy, in Patients with Early Parkinson Disease. Neurology 2017;88:2198-2206.

Publication: Journal Article

Stocchi, F, O Rascol, RA Hauser, S Huyck, A Tzontcheva, R Capece, TW Ho, et al. 2017. “Randomized Trial of Preladenant, Given As Monotherapy, in Patients With Early Parkinson Disease. Neurology 2017;88:2198-2206.”. Neurology.

Factors associated with falling in early, treated Parkinson's disease: The NET-PD LS1 cohort. J Neurol Sci 2017;377:137-143.

Publication: Journal Article

Chou, KL, JJ Elm, CL Wielinski, DK Simon, MJ Aminoff, CW Christine, GS Liang, RA Hauser, L Sudarsky, and . 2017. “Factors Associated With Falling in Early, Treated Parkinson’s Disease: The NET-PD LS1 Cohort. J Neurol Sci 2017;377:137-143.”. J Neurol Sci.

ADS-5102 (Amantadine) Extended-Release Capsules for Levodopa-Induced Dyskinesia in Parkinson Disease (EASE LID Study): A Randomized Clinical Trial. JAMA Neurol 2017;74:941-949.

Publication: Journal Article

Pahwa, R, CM Tanner, RA Hauser, SH Isaacson, PA Nausieda, DD Truong, P Agarwal, et al. 2017. “ADS-5102 (Amantadine) Extended-Release Capsules for Levodopa-Induced Dyskinesia in Parkinson Disease (EASE LID Study): A Randomized Clinical Trial. JAMA Neurol 2017;74:941-949.”. JAMA Neurol.

ADS-5102 (Amantadine) Extended-Release Capsules for Levodopa-Induced Dyskinesia in Parkinson's Disease (EASE LID 2 Study): Interim Results of an Open-Label Safety Study. J Parkinsons Dis 2017;7:511-522.

Publication: Journal Article

Hauser, RA, R Pahwa, CM Tanner, W Oertel, SH Isaacson, R Johnson, L Felt, and MJ Stempien. 2017. “ADS-5102 (Amantadine) Extended-Release Capsules for Levodopa-Induced Dyskinesia in Parkinson’s Disease (EASE LID 2 Study): Interim Results of an Open-Label Safety Study. J Parkinsons Dis 2017;7:511-522.”. J Parkinsons Dis.

Communicating with participants during the conduct of multi-center clinical trials. Clin Trials 2016;13:592-596.

Publication: Journal Article

Augustine, EF, ER Dorsey, RA Hauser, JJ Elm, BC Tilley, and KK Kieburtz. 2016. “Communicating With Participants During the Conduct of Multi-Center Clinical Trials. Clin Trials 2016;13:592-596.”. Clin Trials.

A mixed treatment comparison to compare the efficacy and safety of botulinum toxin treatments for cervical dystonia. J Neurol 2016;263:772-780.

Publication: Journal Article

Han, Y, AL Stevens, K Dashtipour, RA Hauser, and Z Mari. 2016. “A Mixed Treatment Comparison to Compare the Efficacy and Safety of Botulinum Toxin Treatments for Cervical Dystonia. J Neurol 2016;263:772-780.”. J Neurol .

Levodopa-carbidopa intestinal gelin advanced Parkinson's disease: Final 12-month, open-label results. Mov Disord 2015;30:500-9.

Publication: Journal Article

Fernandez, HH, DG Standaert, RA Hauser, AE Lang, VS Fung, F Klostermann, MF Lew, et al. 2015. “Levodopa-Carbidopa Intestinal Gelin Advanced Parkinson’s Disease: Final 12-Month, Open-Label Results. Mov Disord 2015;30:500-9.”. Mov Disord.